Jul 2026 (Q3 FY26) — Aug 26, 2026
Agilent Q3 FY26 — Strong Top and Bottom Line Performance Driven by Ignite and Improving End Markets
Read the full callAgilent (A) earnings
- Jul 2026
- Jul 2026 (Q3 FY26)
- Oct 2025
Agilent earnings: last reported Wed, 26 Aug 2026, for the quarter ended Jul 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 1,878 | +8.1% YoY | Quarterly, as filed | Quarter to Jul 2026 | Revenue from operations as filed. |
| Operating margin | 23.6 | +2.9 pts YoY | Operating profit / revenue | Quarter to Jul 2026 | For the quarter; a change is in percentage points. |
| Net profit | 362 | +7.7% YoY | Quarterly, as filed | Quarter to Jul 2026 | Profit after tax as filed. |
Guidance
What management said, and what became of it
38 of 39 judged targets kept · 44 open · verdicts reflect calls analysed to Jul 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Core revenue growth | roughly 4.4% to 5.9% core growth | Apr 2026 | growing 7.3% on a core basis and exceeding the high end of our guidance by 140 basis points | Achieved |
| China revenue growth | flattish full year | Apr 2026 | We now expect China to grow at mid-single digits | Revised Up |
| ACG revenue growth | mid-single-digit growth | Jul 2026 | We continue to expect mid-single-digit growth for ACG | New |
1 of AGILENT TECHNOLOGIES, INC.'s 83 targets was missed. See which ones, and which are quietly gone. The 3 above are the free sample; 80 more targets are in the full ledger.
Claimed
- Revenue of $1.88 billion, growing 7.3% on a core basis, exceeded the high end of guidance by 140 basis points.
- Operating margin of 27.2% (ex-tariff refunds) was 80 basis points ahead of implied guidance, demonstrating strong operating leverage.
- Earnings per share of $1.56 (ex-tariff refunds) were $0.06 above the high end of guidance, representing robust year-over-year growth of 14%.
- China revenue grew 9%, significantly exceeding flat expectations, driven by strong execution in pharma and food end markets.
- Pharma segment grew 12%, well ahead of high single-digit expectations, with GLP-1 momentum delivering over 70% year-over-year growth.
Qualified
- Diagnostics and Clinical grew 6%, slightly below high single-digit expectations, though underlying orders were robust.
- Academic and Government, the smallest end market, declined 3%, modestly below expectations.
- Europe grew low single digits on a tough year-over-year compare, with geopolitical disruption and delayed CapEx impacting some areas.
- Advanced Therapeutics Division (ATD) is expected to have flattish growth in Q4 FY26 due to a tough year-over-year compare of over 40%.
Price
$169.9 −1.77% · −$3.07
Performance +19.7% 1Y
1Y: $141.92 on 17 Oct 2025 → $169.9. High $175.55 (15 Oct 2026), low $110.24 (27 Mar 2026).
- Previous close
- $172.97
- 52-week range
- $110.24 – $175.55
- One year
- +18.81%
Overview
- Symbol
- A
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
38 of 39 judged targets kept · 44 open · verdicts reflect calls analysed to Jul 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Core revenue growth | roughly 4.4% to 5.9% core growth | Apr 2026 | growing 7.3% on a core basis and exceeding the high end of our guidance by 140 basis points | Achieved |
| China revenue growth | flattish full year | Apr 2026 | We now expect China to grow at mid-single digits | Revised Up |
| ACG revenue growth | mid-single-digit growth | Jul 2026 | We continue to expect mid-single-digit growth for ACG | New |
Claimed
- Revenue of $1.88 billion, growing 7.3% on a core basis, exceeded the high end of guidance by 140 basis points.
- Operating margin of 27.2% (ex-tariff refunds) was 80 basis points ahead of implied guidance, demonstrating strong operating leverage.
- Earnings per share of $1.56 (ex-tariff refunds) were $0.06 above the high end of guidance, representing robust year-over-year growth of 14%.
- China revenue grew 9%, significantly exceeding flat expectations, driven by strong execution in pharma and food end markets.
- Pharma segment grew 12%, well ahead of high single-digit expectations, with GLP-1 momentum delivering over 70% year-over-year growth.
Qualified
- Diagnostics and Clinical grew 6%, slightly below high single-digit expectations, though underlying orders were robust.
- Academic and Government, the smallest end market, declined 3%, modestly below expectations.
- Europe grew low single digits on a tough year-over-year compare, with geopolitical disruption and delayed CapEx impacting some areas.
- Advanced Therapeutics Division (ATD) is expected to have flattish growth in Q4 FY26 due to a tough year-over-year compare of over 40%.
The full ledger
Open AGILENT TECHNOLOGIES, INC.’s full ledger
A free account opens 5 company ledgers a month. All 83 tracked commitments, with each call’s wording and source.
Call summaries
Apr 2026 (Q2 FY26) — May 27, 2026
Agilent Technologies Q2 FY26 — Strong Revenue Growth and Margin Expansion Driven by Ignite System
Read the full callJan 2026 (Q1 FY26) — Feb 25, 2026
Agilent Q1 FY26 — Solid Start with Strong Pharma and CAM Growth, Despite Weather Impact
Read the full callEvery analysed call
Agilent earnings calls (A)
Financials
What the filings say
Net profit, year on year: +8% (quarter to jul 2026 against jul 2025).
| Line item | Oct 2024 | Jan 2025 | Apr 2025 | Jul 2025 | Oct 2025 | Jan 2026 | Apr 2026 | Jul 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,701 | 1,681 | 1,668 | 1,738 | 1,861 | 1,798 | 1,835 | 1,878 |
| Expenses | 1,293 | 1,305 | 1,368 | 1,378 | 1,418 | 1,445 | 1,436 | 1,434 |
| Operating profit | 408 | 376 | 300 | 360 | 443 | 353 | 399 | 444 |
| Operating margin | 24.0% | 22.4% | 18.0% | 20.7% | 23.8% | 19.6% | 21.7% | 23.6% |
| Interest | 32 | 28 | 29 | 28 | 27 | 25 | 25 | 29 |
| Profit before tax | 401 | 367 | 260 | 366 | 442 | 364 | 408 | 444 |
| Tax rate | 12.5% | 13.3% | 17.3% | 8.2% | 1.8% | 16.2% | 16.9% | 18.5% |
| Net profit | 351 | 318 | 215 | 336 | 434 | 305 | 339 | 362 |
| EPS ($ per share) | — | 1.12 | 0.75 | 1.18 | — | 1.08 | 1.20 | 1.28 |
| Line item | Oct 2018 | Oct 2019 | Oct 2020 | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | -336 | -18 | 81 | 348 | 324 | 782 | 750 | 1,389 |
| Total liabilities | 3,970 | 4,704 | 4,754 | 5,316 | 5,227 | 4,918 | 5,948 | 5,986 |
| Fixed assets | 822 | 850 | 845 | 945 | 1,100 | 1,270 | 1,778 | 2,023 |
| Total assets | 8,541 | 9,452 | 9,627 | 10,705 | 10,532 | 10,763 | 11,846 | 12,727 |
| Line item | Oct 2018 | Oct 2019 | Oct 2020 | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1,087 | 1,021 | 921 | 1,485 | 1,312 | 1,772 | 1,751 | 1,559 |
| Cash from investing | -705 | -1,590 | -147 | -749 | -338 | -310 | -1,258 | -394 |
| Cash from financing | -797 | -299 | -717 | -696 | -1,372 | -930 | -752 | -715 |
| Net cash flow | -432 | -866 | 59 | 43 | -434 | 537 | -261 | 459 |
| Capital expenditure | -177 | -155 | -119 | -188 | -291 | -298 | -378 | -407 |
| Free cash flow | 910 | 866 | 802 | 1,297 | 1,021 | 1,474 | 1,373 | 1,152 |
A revenue by segment
Agilent Cross Lab grew from 26% to 42% of revenue over the last two years.
| Segment | Q3 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Agilent Cross Lab | 26% | 41% | 43% | 43% | 41% | 42% | 41% | 42% | +5.6% |
| Life Sciences and Diagnostics Markets | — | 38% | 39% | 39% | 41% | 38% | 40% | 40% | +11.3% |
| Applied Markets | — | 20% | 18% | 19% | 19% | 20% | 19% | 18% | +6.8% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Revenue by region
Q3 FY2026 · share of revenue
- Americas 41% ↑ 1 pt
- Asia Pacific 33%
- Europe 27% ↓ 1 pt
As A cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
74 filings between Nov 12, 2025 and Sep 8, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$3.17M
6 sales by 3 insiders
33% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 28
- Award — granted as compensation
- 1
- Option exercise — converted options into shares
- 36
- Tax withheld — shares kept back by the company to cover tax
Also filed: 3 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| MCDONNELL PADRAIG | — | $2.00M | Nov 18, 2025 |
| Dolsten Mikael | — | $702.2K | Sep 4, 2026 |
| Gonsalves Rodney | — | $465.0K | Nov 26, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 8, 2026 | Boehnlein Glenn S Director | Award | 817 | $120.0K |
| Sep 4, 2026 | Dolsten Mikael Director | Sale | 634 | $96.0K |
| Jun 26, 2026 | KIRKWOOD JONAH PREVOST Senior Vice President | Tax withheld | 30 | $4.1K |
| Jun 3, 2026 | MCDONNELL PADRAIG President and CEO | Tax withheld | 418 | $57.4K |
| May 29, 2026 | Dolsten Mikael Director | Sale | 1,600 | $216.7K |
| May 19, 2026 | Buckner Michael Steven Senior Vice President | Award | 8,872 | $0 |
| May 8, 2026 | MAY SIMON Senior Vice President | Tax withheld | 368 | $42.5K |
| Mar 31, 2026 | Henson Meghan Senior Vice President | Tax withheld | 153 | $17.4K |
| Mar 19, 2026 | Soriot Pascal Director | Award | 2,158 | $241.2K |
| Mar 19, 2026 | Anand Mala Director | Award | 2,158 | $241.2K |
| Mar 19, 2026 | Brown Judy L Director | Award | 2,158 | $241.2K |
| Mar 19, 2026 | Podolsky Daniel K Director | Award | 2,158 | $241.2K |
| Mar 19, 2026 | Rataj Sue H. Director | Award | 2,158 | $241.2K |
| Mar 19, 2026 | Soriot Pascal Director | Tax withheld | 648 | $72.4K |
| Mar 19, 2026 | KOH BOON HWEE Director | Award | 2,158 | $241.2K |
| Mar 19, 2026 | BRAWLEY OTIS W Director | Award | 2,158 | $241.2K |
| Mar 19, 2026 | BRAWLEY OTIS W Director | Award | 888 | $99.2K |
| Mar 19, 2026 | SCANGOS GEORGE A Director | Award | 2,158 | $241.2K |
| Mar 19, 2026 | Dolsten Mikael Director | Award | 2,158 | $241.2K |
| Mar 19, 2026 | SCANGOS GEORGE A Director | Award | 1,057 | $118.1K |
| Mar 19, 2026 | KOH BOON HWEE Director | Tax withheld | 648 | $72.4K |
| Mar 19, 2026 | WILSON DOW R Director | Award | 2,158 | $241.2K |
| Feb 27, 2026 | KIRKWOOD JONAH PREVOST Senior Vice President | Tax withheld | 124 | $15.1K |
| Feb 27, 2026 | RIEMANN ANGELICA Senior Vice President | Tax withheld | 89 | $10.8K |
| Feb 27, 2026 | MCDONNELL PADRAIG President and CEO | Tax withheld | 279 | $33.9K |
| Dec 1, 2025 | Dolsten Mikael Director | Sale | 2,600 | $389.5K |
| Nov 26, 2025 | Gonsalves Rodney V.P., Corporate Controller | Gift | 200 | $30.9K |
| Nov 26, 2025 | Gonsalves Rodney V.P., Corporate Controller | Gift | 200 | $30.9K |
| Nov 26, 2025 | Gonsalves Rodney V.P., Corporate Controller | Gift | 200 | $30.9K |
| Nov 26, 2025 | KIRKWOOD JONAH PREVOST Senior Vice President | Tax withheld | 430 | $66.4K |
| Nov 26, 2025 | Gonsalves Rodney V.P., Corporate Controller | Sale | 3,000 | $465.0K |
| Nov 26, 2025 | Gonsalves Rodney V.P., Corporate Controller | Tax withheld | 119 | $18.4K |
| Nov 26, 2025 | DiMarco Bret Senior Vice President | Tax withheld | 332 | $51.3K |
| Nov 26, 2025 | MCDONNELL PADRAIG President and CEO | Tax withheld | 1,948 | $300.7K |
| Nov 26, 2025 | ZHANG JIANMIAO MIKE Senior Vice President | Tax withheld | 208 | $32.1K |
| Nov 26, 2025 | RIEMANN ANGELICA Senior Vice President | Tax withheld | 280 | $43.2K |
| Nov 26, 2025 | MAY SIMON Senior Vice President | Tax withheld | 300 | $46.3K |
| Nov 21, 2025 | ZHANG JIANMIAO MIKE Senior Vice President | Tax withheld | 67 | $10.1K |
| Nov 21, 2025 | KIRKWOOD JONAH PREVOST Senior Vice President | Tax withheld | 113 | $17.1K |
| Nov 21, 2025 | Gonsalves Rodney V.P., Corporate Controller | Tax withheld | 138 | $20.9K |
| Nov 21, 2025 | RIEMANN ANGELICA Senior Vice President | Tax withheld | 75 | $11.3K |
| Nov 21, 2025 | MCDONNELL PADRAIG President and CEO | Tax withheld | 541 | $81.8K |
| Nov 18, 2025 | MCDONNELL PADRAIG President and CEO | Sale 10b5-1 plan | 911 | $130.5K |
| Nov 18, 2025 | MAY SIMON Senior Vice President | Award | 6,781 | $0 |
| Nov 18, 2025 | KIRKWOOD JONAH PREVOST Senior Vice President | Award | 6,075 | $0 |
| Nov 18, 2025 | KIRKWOOD JONAH PREVOST Senior Vice President | Tax withheld | 772 | $111.0K |
| Nov 18, 2025 | KIRKWOOD JONAH PREVOST Senior Vice President | Award | 1,438 | $0 |
| Nov 18, 2025 | Gonsalves Rodney V.P., Corporate Controller | Award | 2,402 | $0 |
| Nov 18, 2025 | Gonsalves Rodney V.P., Corporate Controller | Tax withheld | 883 | $127.0K |
| Nov 18, 2025 | Gonsalves Rodney V.P., Corporate Controller | Award | 2,540 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for AGILENT TECHNOLOGIES, INC.
Free account. Everything above stays public.
Write why you follow AGILENT TECHNOLOGIES, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading